Publications associées à Chemotherapy regimen

Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy caused by acquisition of genetic alterations during T-cell development. The 5-year overall survival of pediatric T-ALL patients has improved considerably over the past 30 ...

EPFL2023

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Andrea Ablasser

Solid cancers exhibit a dynamic balance between cell death and proliferation ensuring continuous tumour maintenance and growth(1,2). Increasing evidence links enhanced cancer cell apoptosis to paracrine activation of cells in the tumour microenvironment in ...

NATURE PORTFOLIO2022

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Matthias Lütolf, Michele De Palma, Mario Leonardo Squadrito, Mauro Delorenzi, Sina Nassiri, Alan Nicolas Thierry Guichard, Nikolche Gjorevski, Simone Ragusa, Borja Prat Luri, Laureline Wetterwald

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential respon ...

2020

Lymphoma Chemotherapy: Hungry Macrophages Strike the Final Blow

Michele De Palma

Macrophages modulate tumor response to chemotherapy; in this issue, Lossos and colleagues show that high-dose alkylating agents instigate a synthetic lethal program in lymphoma cells that is independent of DNA damage and involves recruitment and priming of ...

AMER ASSOC CANCER RESEARCH2019

Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors

Douglas Hanahan, Gabriele Galliverti

High-risk human papillomavirus (HPV) are responsible for genital and oral cancers associated with the expression of the E6/E7 HPV oncogenes. Therapeutic vaccines targeting those oncogenes can only partially control tumor progression, highlighting the neces ...

2019

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Mauro Delorenzi, Thibaut François Hugo Richard, Yu-Ting Huang

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due ...

Springer2019

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Mauro Delorenzi, Delphine Yvette L Grun

Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients wi ...

AMER SOC CLINICAL INVESTIGATION INC2019

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Michele De Palma, Mario Leonardo Squadrito, Chiara Cianciaruso, Esra Güç, Alan Nicolas Thierry Guichard, Antonino Cassarà

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...

2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Anti-angiogenic immunotherapy for lung cancer

Ece Kadioglu

Lung cancer is the leading cause of cancer-associated deaths worldwide. Platinum-based chemotherapy is the most common therapeutic approach in advanced non-small cell lung cancer (NSCLC), particularly for tumors that carry non-druggable activating mutation ...

EPFL2019

Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment

Paul Joseph Dyson, Tina Riedel, Olivier Pierre Zava

By screening a drug library comprising FDA approved compounds, we discovered a potent interaction between the antifungal agent haloprogin and the experimental organometallic drug RAPTA-T, to synergistically induce cancer cell killing. The combination of th ...

2018

Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Ume-Gulsoom Abdul, Marije Trudi Te Winkel

Cancer cells are often dependent on epigenetic pathways for their survival. Consequently, drugs that target the epigenome, rather than the underlying DNA sequence, are currently attracting considerable attention. In recent years, the first epigenetic drugs ...

Springer Verlag2017

Repositioning approved drugs for the treatment of problematic cancers using a screening approach

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Advances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, ...

2017

Multidimensional Texture Analysis for Improved Prediction of Ultrasound Liver Tumor Response to Chemotherapy Treatment

Dimitri Nestor Alice Van De Ville, Adrien Raphaël Depeursinge

The number density of scatterers in tumor tissue contribute to a heterogeneous ultrasound speckle pattern that can be difficult to discern by visual observation. Such tumor stochastic behavior becomes even more challenging if the tumor texture heterogeneit ...

Springer2016

Development of mass spectrometric methods to understand the mechanism of action of transition metal-based anticancer compounds

Fook Seng Ronald Lee

Metal based anti-cancer drugs (metallodrugs) such as cisplatin are a cornerstone of cancer chemotherapy. However, development of this class of compound has been hindered by our lack of understanding of how they function. This is mainly because existing met ...

EPFL2016

Safe Implementation of Embedded Software for a Portable Device Supporting Drug Administration

Giovanni De Micheli, Yann Thoma, Alena Simalatsar, Wenqi You Dubout

Poor adherence to medical regimen causes approximately 33% to 69% of medication-related hospitalizations and accounts for $100 billion in annual health care costs. In this paper we address the problem of unintentional non adherence, when patient fails to t ...

IEEE2014

Rational design of organic and organometallic thermoresponsive or tumor-selective anticancer drugs and their in vitro and in vivo biological evaluation

Catherine Marie Amélie Clavel

Conventional chemotherapy leads to severe side-effects such as nephrotoxicity, nausea and vomiting and fatigue along with drug resistance. Alkylating agents used to treat cancer were even shown to provoke second cancers, often years after the end of chemot ...

EPFL2014

Macrophage regulation of tumor responses to anticancer therapies

Michele De Palma

Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either enhance or antagonize the antitumor efficacy of cytotoxi ...

2013

Next-Generation Anticancer Metallodrugs

Angela Casini

More than 99% of currently approved clinical drugs are organic compounds. In contrast, the percentage of metal-containing drugs (metallodrugs) is very low. In cancer chemotherapy, however, platinum coordination compounds represented by cisplatin and deriva ...

2010